Mark Robert Warne

Crysalin Ltd. develops crysalin lattice technology for protein structure determination. Its portfolio includes crysalins, a protein-based nanotechnology for application in protein structure determination, as well as biosensor development and optoelectronics. The company was founded by Martin Noble and John Sinclair in June 2007 and is headquartered in Oxfordshire, the United Kingdom.

Iksuda Therapeutics Ltd. operates as a biotechnology company which specializes in the development of next generation biotherapeutics. It creates new generation biological therapeutics through advanced glycosylation and conjugation technologies. The company has core expertise in protein/peptide fictionalization and glycosylation technologies, imparting improved pharmacokinetic properties to a broader range of biological therapeutics. It was founded by David John Simpson and Andrew Watts on November 21, 2007 and is headquartered in Newcastle upon Tyne, the United Kingdom.

Activiomics Ltd. develops innovative technologies that utilize mass spectrometry to interrogate and interpret the activity of cellular signaling pathways. It offers phosphoproteomics for biomaker discovery and drug profiling. The company was founded by Bart Vanhaesebroeck and Pedro Rodriguez Cutillas in 2009 and is headquartered in London, the United Kingdom.

Part of hVIVO PLC, hVIVO Services Ltd. is a British company that specializes in full-service viral challenge studies. The private company is based in London, UK. The company's services include challenge models and lab services. The company was founded in 1988 by John Sidney Oxford.

Optimal Medicine Ltd. offers individualized clinical decision support software for mental health disorders. The firm’s products include ADHD care, behavioral health, and rheumatoid arthritis. Its products employ clinical and genetic information about an individual patient to generate information that guides physicians on the treatment for that patient. The company was founded by Janet Munro and Robert McBurney in 2009 and is headquartered in Newcastle-upon-Tyne, the United Kingdom.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.

Angelini Ventures SpA (Angelini Ventures) is a venture capital firm founded in 2022. The firm is headquartered in Rome, Italy.

Ubiquigent Ltd. develops reagents, kits, drug discovery assay development and compound profiling services to the academic and commercial life science research community worldwide. It focus; namely the ubiquitin, ubiquitin-like and integrated signalling systems. The company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery as well as with pharmaceutical and biotechnology company scientists undertaking ubiquitin system-focused drug discovery. Ubiquigent was founded by Jason Brown in 2009 and is headquartered in Dundee, the United Kingdom.